1.42
+0.02(+1.43%)
Currency In USD
| Previous Close | 1.4 |
| Open | 1.41 |
| Day High | 1.44 |
| Day Low | 1.39 |
| 52-Week High | 3.83 |
| 52-Week Low | 0.22 |
| Volume | 599,033 |
| Average Volume | 986,731 |
| Market Cap | 104.49M |
| PE | -3.02 |
| EPS | -0.47 |
| Moving Average 50 Days | 1.54 |
| Moving Average 200 Days | 1.14 |
| Change | 0.02 |
If you invested $1000 in Cognition Therapeutics, Inc. (CGTX) since IPO date, it would be worth $111.2 as of January 22, 2026 at a share price of $1.42. Whereas If you bought $1000 worth of Cognition Therapeutics, Inc. (CGTX) shares 3 years ago, it would be worth $731.96 as of January 22, 2026 at a share price of $1.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
GlobeNewswire Inc.
Jan 06, 2026 12:30 PM GMT
- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo -PURCHASE, N.Y., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a ma
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
GlobeNewswire Inc.
Dec 03, 2025 12:30 PM GMT
- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January -PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage comp
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
GlobeNewswire Inc.
Dec 01, 2025 12:30 PM GMT
- Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting -- Actively Evaluating Strategy Across DLB and Alzheimer’s Disease - PURCHASE, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or C